✦ LIBER ✦

Idarubicin appears equivalent to dose-intense daunorubicin for remission induction in patients with acute myeloid leukemia

✍ Scribed by Trifilio, Steven; Zhou, Zheng; Mehta, Jayesh; Czerniak, Colleen; Pi, Judy; Greenberg, Deborah; Koslosky, Molly; Pantiru, Mihaela; Altman, Jessica

Book ID: 120504309
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 364 KB
Volume: 37
Category: Article
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2013.04.009

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Intensive timed sequential remission ind

Intensive timed sequential remission induction chemotherapy with high-dose cytarabine for childhood acute myeloid leukemia

✍ Loeb, David M. ;Bowers, Daniel C. ;Civin, Curt I. ;Friedman, Alan D. 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB

## Background: Timed sequential chemotherapy and high-dose cytarabine (cytosine arabinoside, ara-c; hdac) are both effective treatments for acute myeloid leukemia (aml). we review our institutional experience with timed sequential induction chemotherapy consisting of daunorubicin/ara-c/-thioguanine

Randomized study of induction therapy co

Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study

✍ Ohtake, S.; Miyawaki, S.; Fujita, H.; Kiyoi, H.; Shinagawa, K.; Usui, N.; Okumur 📂 Article 📅 2011 🏛 American Society of Hematology 🌐 English ⚖ 194 KB

Superior Long-Term Outcome With Idarubic

Superior Long-Term Outcome With Idarubicin Compared With High-Dose Daunorubicin in Patients With Acute Myeloid Leukemia Age 50 Years and Older

✍ Gardin, C.; Chevret, S.; Pautas, C.; Turlure, P.; Raffoux, E.; Thomas, X.; Quesn 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 184 KB

Long-term follow-up of three randomized

Long-term follow-up of three randomized trials comparing idarubicin and daunorubicin as induction therapies for patients with untreated acute myeloid leukemia

✍ Ellin Berman; Peter Wiernik; Ralph Vogler; Enrique Vélez-Gárcia; Alfred Bartoluc 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 2 views

BACKGROUND. Most clinical trials for acute leukemia have reported results after

Comparison of toxicity and outcome in pa

Comparison of toxicity and outcome in patients with acute myeloid leukemia treated with high-dose cytosine arabinoside consolidation after induction with a regimen containing idarubicin or daunorubicin

✍ G. Seipelt; W.-K. Hofmann; H. Martin; B. Wassmann; A. Boehme; O. G. Ottmann; D. 📂 Article 📅 1998 🏛 Springer 🌐 English ⚖ 205 KB

Idarubicin to intensify the conditioning

Idarubicin to intensify the conditioning regimens of autologous bone marrow transplantation for patients with acute myeloid leukemia in first complete remission

✍ Jerjis, Sh; Roovers, E; Muus, P; Schaap, N; de Witte, T 📂 Article 📅 1998 🏛 Nature Publishing Group 🌐 English ⚖ 68 KB